CClinicalTrials.gg
Sign In
CompletedNCT04845880Updated Apr 15, 2021

SARS Cov_2 Incidence of Healthy Health Workers

An interventional study of Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2 in SARS COV-2 IgG Levels on Health Workers, sponsored by Baskent University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-15.

Sponsored by Baskent University · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2020, registered Apr 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic. The pandemic has affected over 100 countries and regions, with over 132 million confirmed cases of COVID-19. The rapid spread of SARS-CoV-2 has caused considerable harm to public health and the economy. Alongside other laboratory tests and clinical findings of the COVID-19 infection, serological testing may be beneficial for epidemiological monitoring and outbreak control. The determination of antibodies enables confirmation of the SARS-CoV-2 infection in asymptomatic patients in addition to those with typical symptoms. In this study, we aimed to determine the SARS-CoV-2 seroprevalence and the IgG antibody levels among healthcare workers who frequently encountered COVID-19 patients in our hospital.

02

Conditions studied

  • SARS COV-2 IgG Levels on Health Workers
03

In context

Lead sponsor

Baskent University is the lead sponsor of 201 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Healthy Health Workers - SARS COV-2 PCR (-)

Exclusion criteria

Exclusion Criteria:

Health Workers - SARS COV-2 PCR (+) Pregnancy Autoimmune diseases Received immunosuppressive therapy

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
182 participants (actual)

Study arms

  • Other
    SARS Cov_2 Incidence of Healthy Health Workers

    Diagnostic Test: Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2

Interventions

  • Diagnostic testSpike protein (S) or the nucleocapsid (N) of SARS-CoV-2

    Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2

06

What researchers measure

Primary outcomes

  1. Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 patients in Our Hospital

    Determining antibody levels and seroprevalence of healthy healthcare workers

    Time frame: 6 months

07

Study locations

1 site
  • Adana Dr. Turgut Noyan Application and Research Center
    Adana, Turkey
08

References and documents

Publications

  • Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J, Yan F. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-393. doi: 10.1016/j.jinf.2020.02.016. Epub 2020 Feb 26. PubMed 32112884 ↗
  • Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24. PubMed 31986261 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04845880
Lead sponsor
Baskent University
Collaborators
Hikmet Eda Aliskan, Hatice Hale Gumus, Ilker Odemis, Zuhal Ekici Unsal
Responsible party
Hasan Yesilagac (Specialist Doctor, Baskent University) — Principal investigator
First posted
Apr 15, 2021
Start date
Oct 1, 2020
Primary completion
Mar 1, 2021
Completion
Apr 1, 2021
Last update
Apr 15, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Baskent University

Start the discussion